CNS Pharmaceuticals Initiates P-Ib/II Trial of Berubicin for the Treatment of Central Nervous System Lymphoma
Shots:
- The investigator-initiated P-Ib/II trial evaluating the safety, efficacy & PK of Berubicin in adult patients with newly diagnosed or r/r PCNSL & NHL-CNSI at PUM in Szczecin, Poland. ~60 patients intended to enroll while the patients will be entering a post-study follow-up period of ~3yrs. after the end-of-treatment follow-up visit
- The 1EPs are to evaluate the safety & tolerability of Berubicin in combination with other cytostatic agents & the dose escalation strategy's objective is to assess DLT & choose the right dose to use in RP2D. The therapy showed an overall safety profile more favorable over other anthracyclines
- Patients with CNS lymphomas will begin treatment with a higher initial dose of berubicin (4.8 mg/m2) based on P-I trial results
Ref: PRNewswire | Image: CNS Pharmaceuticals
Related News:- Minoryx Therapeutics Entered into a License Agreement with Neuraxpharm for Leriglitazone to Treat Rare Central Nervous System Disease
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
